BioMelbourne Network
Progressing BioIndustry

• Home
• About Us
• Events
• Grants & Awards
• News & Opinion
• Membership
• Resource Library
• Contact

Viralytics moves to increase US presence   19th March 2010, Sydney: Viralytics Limited (ASX: VLA, OTC: VRACY):   Sydney based cancer drug development Company Viralytics Limited (ASX: VLA) has moved to increase its international profile in the lucrative US biotech investment market.   The Company has gained clearance from the US Financial Industry and Regulatory Authority to upgrade its Am... read more…

Tuesday 2nd March 2010, Melbourne Australia: HalcyGen Pharmaceuticals Limited (ASX: HGN) reports that its marketing and distribution partner for its Doryx product, Warner Chilcott (USA), has filed its operating results showing US$66.6 million and US$210.0 million in Doryx sales for the quarter and year ended 31 December 2009 respectively (attached).  The following is an extract of the commentar... read more…

The Brumby Labor Government today invited Victoria’s leading and emerging scientists, engineers and innovators to enter the prestigious 2010 Victoria Prize and Victoria Fellowships. Innovation Minister Gavin Jennings said previous Victoria Prize and Victoria Fellowships winners had pioneered new ways of treating heart failure, stress and high blood pressure as well as the development of polymer... read more…

FUNDING TO GROW VENTURE CAPITAL: CALL FOR FURTHER APPLICATIONS Fund managers around the country are invited to submit applications under the latest round of the Government’s venture capital support program, the Innovation Investment Fund (IIF). Investment in venture capital is a driver of innovation. In the wake of the global recession it is more important than ever to attract investment ... read more…

17 February 2010, Adelaide: LBT Innovations Limited (formerly LabTech Systems) (ASX: LBT), the Australian clinical and diagnostic technology developer, today released its interim results for the half-year to 31 December 2009. For the first half of this financial year revenue and profit after tax decreased compared to the previous corresponding period, the main difference being no revenue from ... read more…

17th February, 2010 - CSL - ASX Accouncement - Interim Result.  Profit $617 million up 23% (up 32% at constant currency)  Cash Flow from Operations $491 million up 10%  CSL Limited today announced a profit after tax of $617 million for the six months ended 31 December 2009, up 23% when compared to the six months ended 31 December 2008. This result included an unfavourable foreign exchange impac... read more…

Senator the Hon Kim Carr, 9th February 2010 Australia’s innovative firms, scientists and researchers are set to benefit from a panel of experts appointed today to serve as the inaugural Commercialisation Australia Board. Commercialisation Australia is a radical new $196 million initiative which takes a hands-on approach to help bring ideas to market by offering a range of tailored assistance ... read more…

5 February 2010, Melbourne: Medical diagnostics company HealthLinx Limited (ASX:HTX) has been awarded the BioSpectrum Asia Product of the Year award 2010 for its ovarian cancer diagnostic OvPlex™. The award was judged by an independent jury of international life sciences experts compiled by BioSpectrum Asia, one of the largest industry magazines in the Asian Pacific region. The jury judged OvPl... read more…

Appendix 4C - Quarterly Cash Flow   Friday 29th January 2010, Melbourne Australia: HalcyGen Pharmaceuticals Limited (ASX: HGN) is pleased to present its Appendix 4C quarterly cash flow for the period to 31st December 2009. The Company has recognised $10.2M of operational cash inflows from two months sales of products for the quarter and a resulting net operational cash inflow for the consolid... read more…

Melbourne: 22nd January, 2010   PapType, Genera Biosystems’ HPV test receives approval from the TGA Genera Biosystems has appointed Lazard as its financial adviser to advise on transaction options available for PapType commercialisation Repeatability/Reproducibility study successfully completed   Genera Biosystems today announced that the Australian Therapeutic Goods Administration (TG... read more…